Pharma's reputation rehab: A whopping two-thirds of Americans now offer a thumbs-up, Harris Poll finds White House: Winter weather caused 6M-dose backlog of COVID-19 vaccines Novavax, coronavirus shot data in hand, strikes an eye-popping supply deal with global vaccine consortium Emergent, partnered with COVID vaccine players J&J and AstraZeneca, works 24/7 to scale up doses KFF: Hospital admissions down 8.2% from March to December 2020 due to COVID-19 As J&J eyes approval for its one-shot COVID-19 vax, it sends off phase 3 data for a swift WHO listing AbbVie, Eli Lilly lead Big Pharma’s 2020 market cap growth as Merck, Gilead lag AI-based voiceprint screener for COVID-19 nets European approval Featured Story | By Beth Snyder Bulik In a stunning reversal from just one year ago, almost two-thirds of Americans now rate the pharma industry positively, The Harris Poll finds. Back in January 2020, as the pandemic was just heating up in the U.S., only about a third gave the industry good marks. read more |
| |
|---|
|
Top Stories By Robert King Extreme winter weather has created a backlog of roughly 6 million COVID-19 doses as workers have been unable to head to distribution sites. read more By Eric Sagonowsky Novavax has sometimes flown under the radar as some of the world's leading drugmakers dominated headlines about the COVID-19 vaccine race. But with key clinical data now in hand, the company has struck an massive new supply deal with international players—and it's sure to turn heads. read more By Fraiser Kansteiner Early in the COVID-19 pandemic, Emergent BioSolutions positioned itself as a manufacturer to beat in the vaccine race. Now, as its partner Johnson & Johnson gears up for a potential U.S. rollout, Emergent is working overtime to get those doses ready. read more By Robert King A new analysis estimated that total hospital admissions were down by roughly 8% compared to the predicted levels from March through December 2020 as the pandemic took a toll. read more By Ben Adams Johnson & Johnson has sent off its phase 3 data package to the World Health Organization for its one-and-done COVID-19 vaccine shot just a few weeks after showing off its efficacy. read more By Angus Liu COVID-19 products aren’t guarantees of market cap growth at biopharma companies these days—and a lack of them doesn’t deprive a drugmaker, either—if a year-end comparison between 2020 and 2019 is any indication. read more By Conor Hale From taste and smell to muscle aches and “COVID toes,” the coronavirus affects the body in a variety of ways—including small changes in a person’s voice, subtle to the ear but clear enough to spot on a computer, according to Vocalis Health. read more |
